Cell aging
Laboratory research. Experimental research; clinical benefit is not established.1
Recovery
Cartalax
AED and aging-cell research
Investigational; this profile does not establish an approved use.
What does it do?
Cartalax refers to Ala–Glu–Asp, an experimental tripeptide. Verified work includes aging-cell experiments. Pep-Pedia’s named spine/joint study lacks an original-source link, so it cannot establish clinical joint benefit here.
Joint support
Reported by Pep-Pedia; not an established clinical indication.2
Molecular information
1Amino-acid sequence
- Ala
- Glu
- Asp
3 residues · N → C1
Length3 amino acids
Molecular weight · DaNot independently verified
Molecular formulaNot independently verified1
A–E–DSequence and formulation must be confirmed for the exact material; similarly named products are not necessarily interchangeable.
How long does it stay in the body?
Pharmacokinetics · How quickly the compound clears.
Half-lifeHuman kinetics not established1
No numerical human elimination estimate is assigned from animal experiments, related molecules, or an unsupported website estimate.
There is not enough numerical information in the checked sources to show a clearance curve.
What to expect
Study outcomes
Scope of evidence
No adequately identified human joint trial was verified.1
Doses by goal
These are reported practices from secondary sources, not validated dosing recommendations.
Route
Scroll to compare all columns →
| Goal | Dose | Frequency | Route | Duration | Source |
|---|---|---|---|---|---|
| Standard Protocol | 1 capsule (100 mcg) | Daily with meals | Oral | 1-3 months | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| Intensive Support | 2 capsules (200 mcg) | Daily with meals | Oral | 1-3 months | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| Maintenance | 1 capsule (100 mcg) | Every other day with food | Oral | 1-3 months | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| Standard Protocol | 10 mcg/kg (700 mcg for 70kg) | Daily | SubQ | 20-30 days | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| Intensive Protocol | 15 mcg/kg (1050 mcg for 70kg) | Daily | SubQ | 20-30 days | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| Maximum Research Dose | 20 mcg/kg (1400 mcg for 70kg) | Daily | SubQ | 20-30 days | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| Maintenance | 10 mcg/kg (700 mcg for 70kg) | Every other day | SubQ | 20-30 days | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| Facial Anti-Aging | 0.5ml | Twice daily | Topical | 30-60 days | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Topical | |||||
| Body Application | 1ml | Daily | Topical | 30-60 days | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Topical | |||||
| Joint Areas | 0.5-1ml | Twice daily | Topical | 30-60 days | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Topical | |||||
No protocols match these filters.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Oral
- Use period
- 1-3 months
- Break
- 3-6 months between courses
Reported timing
With breakfast and/or dinner as recommended by manufacturer
Injectable
- Use period
- 20-30 days
- Break
- 1-2 months between cycles
Reported timing
Morning administration for tissue repair throughout the day
Topical
- Use period
- 30-60 days
- Break
- 1 month between cycles
Reported timing
After cleansing, before moisturizer
Side effects & safety
Missing clinical source
The named clinical spine/joint card has no original-source link, so efficacy and adverse events cannot be assessed.
2Different sequence
Cartalax is AED; KED is Vesugen. Confusing these names misassigns the evidence.
1Symptoms
Persistent GI/skin/injection irritation, allergy, unusual tissue growth, joint swelling, skin changes, excessive dryness/oiliness or worsening symptoms need assessment.
Limitations
Active-cancer concerns theoretical; pregnancy/lactation and route-specific safety unknown.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
IGF-1 / GH
Caution reportedProliferation concern.9
Reference report · Pep-Pedia label: Monitor CombinationKhavinson peptides: Epitalon / Thymalin
Unverified pairingOrgan-target rationale.9
Reference report · Evidence context: Synergy claim (unvalidated)Collagen
Unverified pairingMatrix substrate rationale.9
Reference report · Pep-Pedia label: SynergisticBPC-157
Unverified pairingReported general-repair/cartilage pairing; untested.9
Reference report · Pep-Pedia label: CompatibleTB-500
Unverified pairingProposed actin/fibroblast complement; untested.9
Reference report · Pep-Pedia label: CompatibleAnti-inflammatory medications
Unverified pairingProposed tissue-support/inflammation pairing; interaction safety unknown.9
Reference report · Pep-Pedia label: CompatibleGlucosamine / Chondroitin
Unverified pairingJoint-support rationale.9
Reference report · Pep-Pedia label: SynergisticImmunosuppressants
Unverified pairingNo interaction studies.9
Reference report · Evidence context: UnknownOther peptides and medicines
Not establishedA controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.2
Research contextNo matching interactions. Try another name or filter.
Reconstitution
A product-specific preparation or sterility protocol has not been verified.2
Dilution
A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.2
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Oral
The source describes oral capsules containing 0.1 mg (100 mcg) of peptide complex.
- Form
- Source describes a prepared product
- Reported parameters
- Reported handling: swallow intact with meals; keep dry.
Injectable
Pep-Pedia gives a concentration example for a 20 mg vial.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- 20 mg in 2 mL gives 10 mg/mL. · At that concentration, 1 mg occupies 0.1 mL (10 U-100 syringe units). · Reported storage: refrigerated and protected from light.
The source describes gentle mixing and avoiding vigorous shaking.
Topical
The topical section refers to a carrier and optional penetration-enhancing base; it gives no named diluent.
- Reported parameters
- The source provides no validated topical stability specification.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearancePharmaceutical packagingReported appearanceCorrect capsule contentReported appearanceClear dosing instructionsReported variationImport verificationReported appearanceManufacturer compliance
9Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.9
Storage notes
9Room temperature in dry place
Refrigerate at 2-8°C, protect from light
Refrigerate prepared solutions
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →No adequately identified human joint trial was verified.1
Early research. The relevant evidence is mainly from cells or animals. Human biomarker associations do not show what happens when people take the compound.
Evidence definitions →Research findings
PreclinicalCompound identity & other names
Cartalax refers to Ala–Glu–Asp, an experimental tripeptide. Verified work includes aging-cell experiments. Pep-Pedia’s named spine/joint study lacks an original-source link, so it cannot establish clinical joint benefit here.
Other names: AED · T-31
Investigational; this profile does not establish an approved use.
Ala–Glu–Asp (AED); not Lys–Glu–Asp (Vesugen)1
How it may work
Proposed Ki-67, p53, fibroblast and epigenetic changes; oral absorption unestablished.9
Aging fibroblast cultures
AED suppressed caspase-dependent apoptosis in aging fibroblast cultures; the experiment did not measure joint pain, cartilage repair in patients, or lifespan.
1Research areas and evidence gaps
Cell aging. Experimental research; clinical benefit is not established.1
- No adequately identified human joint trial was verified.
- The evidence does not validate the identity, purity or handling of a separately sourced research product.
Additional uses listed by Pep-Pedia
Joints. Cartilage, osteoarthritis/osteochondrosis, degeneration prevention and fracture/injury recovery.9
Skin. Fibroblasts, collagen/elastin, wrinkles, elasticity, microcirculation and minor-wound claims.9
Cellular. Apoptosis, stem-cell maintenance and extracellular-matrix preservation.9
Community reports Unvalidated
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.2
Community protocol tables are unvalidated descriptions, not treatment instructions.
Search coverage and review status
Additional primary or regulatory sources were checked. No further 2025–2026 exact-compound clinical outcome study was identified in this targeted search; this is not evidence that none exists.
- Checked
- 2026-10-12
- Search
- Cartalax OR Lys-Glu-Asp peptide 2025 2026 study; Cartalax peptide; Cartalax study peptide fibroblasts
- Catalog
- Pep-Pedia ↗ · 6 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
- An initial search used the incorrect synonym KED; corrected identity is AED (Ala–Glu–Asp). KED is Vesugen.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 4 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “571 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1Peptide Regulation of Skin Fibroblast Functions during Their Aging In VitroAbstract checked
AI-PREPARED SUMMARY
AED and other short peptides changed proliferation, matrix-remodeling and apoptosis markers in aging skin-fibroblast cultures.
Aging fibroblast cultures
AED suppressed caspase-dependent apoptosis in aging fibroblast cultures; the experiment did not measure joint pain, cartilage repair in patients, or lifespan.
Additional research · Checked 2026-10-12
2Pep-Pedia: CartalaxCommunity source checked
AI-PREPARED SUMMARY
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
3Neuronal Differentiation Study (2022)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Periodontal stem-cell cultures showed increased proliferation and neuronal differentiation after exposure to several peptide bioregulators.
Reported population / model
Periodontal ligament stem cells
Reported study details
0.1 μg/ml · 7 days · Enhanced differentiation
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4Bone Marrow Stem Cell Study (2021)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Bone-marrow stromal cells showed changes in aging-related gene expression; this does not establish tissue regeneration in people.
Reported population / model
MSCs
Reported study details
10-100 nM · 14 days · Gene expression changes
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Kidney Cell Culture Research (2020)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Aging kidney-cell cultures reportedly expressed less p53; effects on lifespan or clinical kidney disease were not established.
Reported population / model
Renal epithelial cells
Reported study details
Various doses · 7 days · Reduced p53
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Matrix Metalloproteinase Research (2020)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Fibroblast cultures reportedly produced less MMP-9, a matrix-degrading enzyme; patient joint outcomes were not assessed.
Reported population / model
Fibroblast cultures
Reported study details
20 nM · 5 days · Reduced MMP-9
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Fibroblast Proliferation Study (2019)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Cultured fibroblasts showed higher Ki-67/CD98hc and lower caspase-3-related apoptosis; these are laboratory markers, not human anti-aging outcomes.
Reported population / model
Human skin fibroblasts
Reported study details
20 nM · 72 hours · Increased Ki-67
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Clinical Spine & Joint Study (Russia)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Improved mobility and joint function are claimed in Russian clinical use, but the card supplies no participant count, comparator or primary-study link.
Reported population / model
Human
Reported study details
0.1mg capsules daily · 1-3 months · Improved mobility
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Pep-Pedia: Cartalax — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12